Do Not Switch to High-Dose Trimbow
You should continue your current regimen of Fostair (beclomethasone 400 µg daily) plus Spiriva Respimat (tiotropium) rather than switching to high-dose Trimbow. Your current therapy already provides the same three active components (ICS/LABA/LAMA) that Trimbow offers, and there is no evidence that consolidating into a single inhaler improves clinical outcomes when you're already receiving optimal triple therapy.
Why Your Current Regimen is Appropriate
Your current treatment strategy aligns with established asthma management guidelines. You are receiving:
- Medium-dose ICS/LABA (Fostair 400 µg beclomethasone daily)
- LAMA add-on (Spiriva Respimat/tiotropium)
This represents guideline-concordant triple therapy for uncontrolled persistent asthma 1, 2. The 2020 NAEPP guidelines specifically recommend adding LAMA to ICS-LABA in patients aged 12 years and older with uncontrolled persistent asthma 2.
Evidence for LAMA Add-On to ICS/LABA
The addition of tiotropium (Spiriva Respimat) to ICS/LABA therapy has demonstrated:
- Improved lung function (peak and trough FEV1) 3
- Enhanced asthma control (ACT scores) 3
- Reduced risk of severe exacerbations 3
- Efficacy independent of baseline patient characteristics including age 3, 4
These benefits occur when tiotropium is added to medium-dose ICS 3, which is precisely your current regimen.
Single-Inhaler Triple Therapy Considerations
While recent studies show that single-inhaler BDP/formoterol/glycopyrronium (Trimbow) is effective 5, 6, 7, the evidence demonstrates:
Key Point: The clinical trials comparing Trimbow to other regimens primarily enrolled patients who were not already on triple therapy 5, 6. Most patients in these studies were transitioning from ICS/LABA combinations, not from established ICS/LABA + LAMA therapy like yours.
The TriMaximize real-world study showed that before starting Trimbow, only 43.2% of patients on high-dose formulations were receiving free ICS/LABA/LAMA combinations 5. This means the improvements seen were largely in patients stepping up therapy, not switching between equivalent triple therapy regimens.
Practical Considerations
Device and Adherence Factors:
- Your current two-inhaler approach is working if your asthma is controlled
- Single-inhaler therapy's main advantage is potentially improved adherence 8
- However, if you're already adherent to your current regimen, consolidation offers no additional clinical benefit
- The extrafine formulation in Trimbow may improve small airway deposition 8, but this theoretical advantage hasn't been proven superior to your current regimen in head-to-head trials
Dosing Equivalence:
- Your Fostair 400 µg daily = medium-dose ICS
- High-dose Trimbow (172/5/9 µg) would represent a step-up in ICS dose
- This step-up is only warranted if your asthma remains uncontrolled on current therapy
When to Consider Switching
You should only consider switching to Trimbow if:
- Poor adherence to your two-inhaler regimen is documented and contributing to poor control
- Device technique issues with either current inhaler that cannot be corrected with education
- Persistent uncontrolled asthma despite confirmed adherence and proper technique with current therapy (in which case, high-dose Trimbow would represent appropriate step-up therapy)
- Cost or access issues make the single-inhaler option more feasible
Assessment Before Any Change
Before considering any switch, verify:
- Adherence: Are you taking both inhalers as prescribed?
- Technique: Can you demonstrate proper use of both devices?
- Control: What is your current ACT score? Exacerbation frequency? Rescue inhaler use?
- Environmental triggers: Are modifiable factors contributing to symptoms?
The 2020 NAEPP guidelines emphasize checking adherence and environmental control before escalating therapy 2, and this principle applies equally to lateral switches between equivalent regimens.
Bottom Line
Your current combination of Fostair plus Spiriva Respimat already provides triple therapy (ICS/LABA/LAMA) that is guideline-recommended and evidence-based for uncontrolled asthma 2, 3. Switching to Trimbow would simply consolidate the same medication classes into one device without proven superiority in outcomes. Reserve the switch for situations where device consolidation specifically addresses an identified barrier to optimal asthma control, such as documented non-adherence or technique problems with your current inhalers.